Galili N - Search Results

1

Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes.

Wang R, Gross CP, Maggiore RJ, Halene S, Soulos PR, Raza A, Galili N, Ma X. Wang R, et al. Among authors: galili n. Leuk Res. 2011 Jul;35(7):904-8. doi: 10.1016/j.leukres.2010.10.007. Epub 2010 Nov 9. Leuk Res. 2011. PMID: 21067809 Free PMC article.

2

Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes.

Ma X, Wang R, Galili N, Mayne ST, Wang SA, Yu H, Raza A. Ma X, et al. Among authors: galili n. Cancer Causes Control. 2011 Apr;22(4):623-9. doi: 10.1007/s10552-011-9735-6. Epub 2011 Feb 2. Cancer Causes Control. 2011. PMID: 21287258 Free PMC article.

3

The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.

Wang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X. Wang R, et al. Among authors: galili n. Leuk Res. 2012 Nov;36(11):1370-5. doi: 10.1016/j.leukres.2012.07.020. Epub 2012 Aug 20. Leuk Res. 2012. PMID: 22917770 Free PMC article.

4

Clinical response of myelodysplastic syndromes patients to treatment with coenzyme Q10.

Galili N, Sechman EV, Cerny J, Mehdi M, Mumtaz M, Westervelt P, Maguire J, Raza A. Galili N, et al. Leuk Res. 2007 Jan;31(1):19-26. doi: 10.1016/j.leukres.2006.04.009. Epub 2006 Oct 24. Leuk Res. 2007. PMID: 17064768 Clinical Trial.

5

Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.

Yue G, Hao S, Fadare O, Baker S, Pozdnyakova O, Galili N, Woda BA, Raza A, Wang SA. Yue G, et al. Among authors: galili n. Leuk Res. 2008 Apr;32(4):553-8. doi: 10.1016/j.leukres.2007.08.006. Epub 2007 Sep 20. Leuk Res. 2008. PMID: 17888511

6

Clinical implications of gene expression profiling in myelodysplastic syndromes: recognition of ribosomal and translational gene dysregulation and development of predictive assays.

Galili N, Raza A. Galili N, et al. Best Pract Res Clin Haematol. 2009 Jun;22(2):223-37. doi: 10.1016/j.beha.2009.04.006. Best Pract Res Clin Haematol. 2009. PMID: 19698930

7

Prognosis in myelodysplastic syndromes: are the new classifications useful?

Galili N, Raza A. Galili N, et al. Curr Hematol Malig Rep. 2008 Jan;3(1):19-22. doi: 10.1007/s11899-008-0004-z. Curr Hematol Malig Rep. 2008. PMID: 20425442

8

Pharmacotherapy of myelodysplastic syndromes.

Galili N, Raza A. Galili N, et al. Expert Opin Pharmacother. 2010 Aug;11(11):1889-99. doi: 10.1517/14656566.2010.485613. Expert Opin Pharmacother. 2010. PMID: 20486832 Review.

9

The biology and treatment of myelodysplastic syndromes.

Raza A, Galili N. Raza A, et al. Among authors: galili n. Rinsho Ketsueki. 2013 Oct;54(10):1730-6. Rinsho Ketsueki. 2013. PMID: 24064823 Review. No abstract available.

10

Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.

Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G. Raza A, et al. Among authors: galili n. Leuk Res. 2004 Aug;28(8):791-803. doi: 10.1016/j.leukres.2003.11.018. Leuk Res. 2004. PMID: 15203277

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

115 results

Search Page

Filters